INKT MiNK Therapeutics, Inc.

NASDAQ

$12.18

MiNK Therapeutics, Inc. (INKT) Earnings News

Earnings press releases, previews and reviews for MiNK Therapeutics, Inc. (INKT), newest first.

Thursday August 13, 2026 7:30 AM ET

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

Thursday August 6, 2026 8:19 AM ET

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

Friday May 15, 2026 7:30 AM ET

MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

Friday May 8, 2026 4:30 PM ET

MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs

Tuesday March 31, 2026 7:30 AM ET

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum